查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464812

脑血管疾病治疗市场：依治疗方式、产品类型、疾病类型、最终用户划分 - 全球预测 2024-2030

Cerebrovascular Diseases Treatment Market by Treatment Modality (Endovascular Procedures, Medical Management, Surgical Intervention), Products (Devices, Drug Medication), Disease Type, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年脑血管疾病治疗市场规模为51.2亿美元，预计2024年将达54亿美元，2030年将达75.9亿美元，复合年增长率为5.76%。

脑血管疾病包括影响大脑及其血管的脑循环的多种疾病。具体而言，它包括中风、短暂性脑缺血发作(TIA)、动脉瘤和血管畸形等疾病。脑血管疾病的治疗是多方面的，旨在预防高风险族群发病、解决急性症状以及控制诊断后的长期影响。根据具体病理、严重程度和患者的整体健康状况，治疗方法会有很大差异。特定治疗策略的选择取决于综合方法，包括患者的病历、脑血管疾病的类型和严重程度以及医疗团队的专业知识。世界人口老化，更容易患中风和动脉瘤等脑血管疾病，以及神经血管护理医疗费用的不断上涨，正在推动脑血管疾病治疗市场的扩张。然而，新兴市场的治疗和手术费用高昂以及获得先进医疗设施的机会有限是阻碍市场扩张的主要因素。医学进步不断推动脑血管疾病治疗的发展，预计未来将为患者提供更有效和个人化的选择。

主要市场统计
基准年[2023] 51.2亿美元
预测年份 [2024] 54亿美元
预测年份 [2030] 75.9亿美元
复合年增长率（%） 5.76%

治疗方式：越来越多采用微创血管内治疗

血管内治疗方法是治疗脑血管疾病的前沿方法，利用微创技术来治疗动脉瘤、动静脉畸形 (AVM) 和急性缺血性脑中风等病理。此方法主要包括血管成形术、置入术和栓塞术等技术。与传统手术相比，血管内治疗具有独特的优势，即恢復时间较短，且併发症的风险较低。医疗管理是脑血管疾病治疗的基石，重点是透过药物介入控制症状和预防疾病进展。这种治疗方法包括使用抗凝血剂和抗血小板药物来防止血栓形成、使用抗高血压药物来控制血压、在缺血性中风的情况下使用他汀类药物来降低胆固醇水平，以及组织纤维蛋白溶酶原活化剂。医疗管理旨在最大限度地降低未来脑血管事件的风险，管理相关的危险因素，缓解症状并改善患者的生活品质。当仅透过血管内治疗或药物治疗无法充分治疗脑血管疾病时，需要进行手术介入。这种治疗方法包括颈动脉内膜切除术 (CEA) 等手术。 CEA 涉及手术移除颈动脉斑块或手术夹闭或盘绕动脉瘤，以预防颈动脉严重狭窄患者中风。儘管这些治疗方法比其他治疗方法更具侵入性和风险，但它们可以挽救生命，并且对于管理严重併发症和死亡高风险的病理至关重要。

最终用户医院和外科中心对脑血管疾病治疗的需求不断增加

在门诊手术中心，脑血管疾病的治疗重点是诊断、管理和后续观察，而不是侵入性手术。这些中心更适合需要持续治疗和监测而无需住院的患者。服务包括服用抗凝血剂和抗血小板药物等药物、监测以防止症状恶化，以及提供生活方式咨询以支持康復并降低未来脑血管事故的风险。医院和外科中心对于治疗脑血管疾病，特别是急性和重症病例至关重要。这些设施可以进行先进的诊断测试、紧急干预和外科手术，例如颈动脉内膜切除术、置入术和动脉瘤夹闭术。也提供即时术后照护和强化復健服务，以确保患者康復并最大程度地减少长期残疾。此外，这些中心协调多学科护理，包括神经科、外科医生和治疗师，以解决患者病情的各个方面。儘管实验室和学术机构不直接参与患者护理，但它们为脑血管疾病新治疗方法的开发做出了重要贡献。这些设施进行基础和临床研究，以了解疾病的病理学，从而发现新的治疗标靶。此外，他还负责测试新药物、设备和治疗通讯协定的安全性和有效性的临床试验。这些研究的结果可能有助于增强现有的治疗方法，并提供创新的解决方案来改善患者的治疗结果。

区域洞察

美洲脑血管疾病治疗市场的特点是医疗基础设施先进，对中风、动脉瘤等脑血管疾病的认知度较高。美国研发投入活跃，医药和医疗设备业者实力雄厚，并获得政府政策支持。在美国，非侵入性治疗和个人化医疗有明显的趋势。成长要素包括人口老化、高血压和糖尿病的流行以及不健康生活习惯的养成。在亚太地区，由于医疗成本上升、人们对中风和其他脑血管疾病的认识不断提高以及医疗基础设施的改善，脑血管疾病治疗市场正在快速成长。尤其是中国、印度等人口老化严重的国家，是重要的市场。负担得起且易于获得的治疗方法的创新以及政府加强医疗保健系统的倡议预计将推动亚太地区脑血管疾病治疗市场的成长。欧洲、中东和非洲地区为脑血管疾病的治疗提供了多元化的市场环境，其中欧洲因其研发活动和医疗保健支出而成为重要市场。人口老化和生活方式影响欧洲脑血管疾病的盛行率。由于医疗保健投资的增加和医疗服务的改善，中东和非洲的脑血管疾病治疗市场正在扩大。创新治疗方法和政府措施对于这些地区的市场扩张至关重要。

FPNV定位矩阵

FPNV定位矩阵对于评估脑血管疾病治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对脑血管疾病治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.脑血管疾病治疗市场的市场规模与预测是多少？

2.在脑血管疾病治疗市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.脑血管疾病治疗市场的技术趋势和法规结构是什么？

4.脑血管疾病治疗市场主要供应商的市场占有率是多少？

5.进入脑血管疾病治疗市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对脑​​血管疾病的认识以及早期筛检的重要性
      • 随着全球人口持续老化，医疗保健费用也增加。
    • 抑制因素
      • 脑血管治疗费用高
    • 机会
      • 在神经血管护理方面进行了大量的研究和开发工作
      • 用于治疗脑血管疾病的设备的进展
    • 任务
      • 副作用风险和缺乏熟练专业人员的风险
  • 市场区隔分析
    • 治疗方法：血管内治疗因其微创性而被越来越多地采用
    • 最终使用者：医院和外科中心对脑血管疾病治疗的需求不断增加
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章依治疗方法分類的脑血管疾病治疗市场

  • 血管内手术
  • 医疗管理
  • 手术治疗

第七章脑血管疾病治疗市场：副产品

  • 装置
  • 药物治疗

第八章脑血管疾病治疗市场：依疾病类型

  • 出血性中风
  • 缺血性中风
  • 短暂性脑缺血发作（TIA）

第九章脑血管疾病治疗市场：依最终使用者分类

  • 门诊治疗中心
  • 医院和外科中心
  • 研究实验室和学术机构

第十章 北美、南美脑血管疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区脑血管疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东、非洲脑血管疾病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Serenovus推出中间导管“Seleglide 71”，用于急性缺血性脑中风患者的重组
    • Enzen Biosciences 推出雷珠单抗生物相似药，用于治疗新生血管性老龄化黄斑部病变(AMD)
    • Cooper 和 Inspira 合作扩大新泽西州南部的神经科学护理
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F97DD5A7D993

[190 Pages Report] The Cerebrovascular Diseases Treatment Market size was estimated at USD 5.12 billion in 2023 and expected to reach USD 5.40 billion in 2024, at a CAGR 5.76% to reach USD 7.59 billion by 2030.

Cerebrovascular diseases encompass a range of conditions that affect the cerebral circulation of the brain and its blood vessels. Most notably, these include diseases such as stroke, transient ischemic attack (TIA), aneurysms, and vascular malformations. Treatment for cerebrovascular diseases is multifaceted, designed to either prevent the onset of these conditions in at-risk individuals or to address acute conditions and manage long-term effects post-diagnosis. Treatment modalities vary widely based on the specific condition, its severity, and the patient's overall health. The selection of specific treatment strategies depends on an integrated approach involving the patient's medical history, the type and severity of the cerebrovascular disease, and the expertise of the healthcare team. The rising aging population globally, which is more susceptible to cerebrovascular diseases such as strokes and aneurysms, and the increasing healthcare expenditures in neurovascular care drive the cerebrovascular diseases treatment market expansion. However, the high cost of treatments and surgeries and limited access to the advanced healthcare facilities in developing regions are key factors hindering the market growth. Advances in medical science continue to evolve the landscape of cerebrovascular disease treatment, promising more effective and personalized options for patients moving forward.

KEY MARKET STATISTICS
Base Year [2023] USD 5.12 billion
Estimated Year [2024] USD 5.40 billion
Forecast Year [2030] USD 7.59 billion
CAGR (%) 5.76%

Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature

Endovascular procedures represent a forefront approach to treating cerebrovascular diseases, leveraging minimally invasive techniques to address conditions such as aneurysms, arteriovenous malformations (AVMs), and acute ischemic strokes. This modality primarily includes techniques such as angioplasty, stenting, and embolization. Endovascular procedures are particularly advantageous due to their minimized recovery times and lower risk of complications compared to traditional surgery. Medical management is a cornerstone in treating cerebrovascular diseases, focusing on controlling symptoms and preventing disease progression through pharmaceutical interventions. This modality includes the administration of anticoagulants and antiplatelet agents to prevent clot formation, antihypertensive drugs to control blood pressure, and statins to reduce cholesterol levels for conditions such as ischemic stroke, medications including tissue plasminogen activator (tPA) may be used to dissolve the clot causing the stroke if administered within a specific time window after symptom onset. Medical management aims to minimize the risk of future cerebrovascular events, manage associated risk factors, and provide symptomatic relief, improving patients' quality of life. Surgical intervention is utilized in cases where cerebrovascular diseases cannot be adequately managed through endovascular procedures or medical management alone. This treatment modality may involve procedures such as carotid endarterectomy (CEA), where plaque is surgically removed from the carotid artery for preventing stroke in patients with significant carotid artery stenosis or surgical clipping and coiling for aneurysms. Though these interventions are more invasive and carry greater risk than other treatment modalities, they can be life-saving and are critical for managing conditions that pose a high risk of serious complications or death.

End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers

In ambulatory care centers, treatments for cerebrovascular diseases are primarily focused on diagnosis, management, and follow-up care rather than invasive surgical procedures. These centers provide accessibility for patients requiring ongoing treatment or monitoring without hospital admission. Services include administering medications, such as anticoagulants and antiplatelets, monitoring symptoms to prevent progression, and lifestyle counseling to support rehabilitation and reduce the risk of future cerebrovascular events. Hospitals and surgical centers are critical in treating cerebrovascular diseases, especially acute and severe cases. These facilities can perform advanced diagnostic tests, emergency interventions, and surgical procedures such as carotid endarterectomy, stenting, and aneurysm clipping. Immediate post-operative care and intensive rehabilitation services are also provided to ensure patient recovery and minimize long-term disabilities. Additionally, these centers coordinate multidisciplinary care involving neurologists, surgeons, and therapists to address all aspects of the patient's condition. While not directly involved in patient care, research laboratories, and academic institutes significantly contribute to developing new treatments for cerebrovascular diseases. These establishments conduct fundamental and clinical research to understand the pathophysiology of diseases, leading to the discovery of novel therapeutic targets. Furthermore, they are responsible for the clinical trials that test the safety and efficacy of novel drugs, devices, and treatment protocols. Insights gained from these studies aid in enhancing existing treatment approaches and potentially offer innovative solutions to improve patient outcomes.

Regional Insights

The market for cerebrovascular disease treatment in the Americas is characterized by advanced healthcare infrastructure and a high degree of awareness about cerebrovascular diseases such as stroke and aneurysms. The United States has robust R&D investments, a strong presence of pharmaceutical and medical device companies, and supportive government policies. The American region showcases a trend towards non-invasive procedures and personalized medicine. Growth factors include the aging population, the prevalence of hypertension and diabetes, and the adoption of unhealthy lifestyle habits. The Asia-Pacific region presents a rapidly growing cerebrovascular disease treatment market driven by increasing healthcare expenditure, rising awareness about stroke and other cerebrovascular conditions, and improving healthcare infrastructure. The countries such as China and India are particularly significant markets with large aging populations. Innovations in affordable and accessible treatments and governmental efforts to enhance healthcare systems are expected to propel cerebrovascular disease treatment market growth in the Asia-Pacific region. The EMEA region exhibits a diverse market landscape for cerebrovascular disease treatment, with Europe being a significant market due to its research and development activities and healthcare spending. An aging population and lifestyle factors influence the prevalence of cerebrovascular diseases in Europe. The cerebrovascular diseases treatment market in the Middle East and Africa is expanding, driven by increasing healthcare investments and improving access to care. Innovative treatments and government initiatives are crucial for market expansion in these regions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cerebrovascular Diseases Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cerebrovascular Diseases Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cerebrovascular Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, AstraZeneca plc, Bayer AG, BIOGEN INC., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., GE HealthCare Technologies Inc., Genentech, Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Medtronic plc, Merck & Co., Inc., Penumbra, Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sanofi SA, Siemens Healthineers AG, Sihuan Pharmaceutical Holdings Group Ltd., Takeda Pharmaceutical Co. Ltd., and United Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the Cerebrovascular Diseases Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Modality
    • Endovascular Procedures
    • Medical Management
    • Surgical Intervention
  • Products
    • Devices
      • Carotid Stents
      • Cerebral Balloon Angioplasty and Stenting Systems
      • Clot Retrieval Devices
      • Coil Embolization Devices
      • Embolic Protection Systems
      • Flow Diverter Devices
      • Intracranial Stents
    • Drug Medication
      • Anticoagulants
      • Antihypertensive Drugs
      • Antiplatelet Drugs
      • Cholesterol-lowering Drugs
      • Thrombolytics
  • Disease Type
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Transient Ischemic Attack (TIA)
  • End-user
    • Ambulatory Care Centers
    • Hospitals & Surgical Centers
    • Research Laboratories & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cerebrovascular Diseases Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cerebrovascular Diseases Treatment Market?

3. What are the technology trends and regulatory frameworks in the Cerebrovascular Diseases Treatment Market?

4. What is the market share of the leading vendors in the Cerebrovascular Diseases Treatment Market?

5. Which modes and strategic moves are suitable for entering the Cerebrovascular Diseases Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness regarding cerebrovascular diseases and the importance of early screening
      • 5.1.1.2. The rising aging population globally and the increasing healthcare expenditures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cerebrovascular treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Substantial R&D initiatives in neurovascular care
      • 5.1.3.2. Advancements in devices used for cerebrovascular disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects and lack of skilled professional
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature
    • 5.2.2. End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cerebrovascular Diseases Treatment Market, by Treatment Modality

  • 6.1. Introduction
  • 6.2. Endovascular Procedures
  • 6.3. Medical Management
  • 6.4. Surgical Intervention

7. Cerebrovascular Diseases Treatment Market, by Products

  • 7.1. Introduction
  • 7.2. Devices
  • 7.3. Drug Medication

8. Cerebrovascular Diseases Treatment Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Hemorrhagic Stroke
  • 8.3. Ischemic Stroke
  • 8.4. Transient Ischemic Attack (TIA)

9. Cerebrovascular Diseases Treatment Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Care Centers
  • 9.3. Hospitals & Surgical Centers
  • 9.4. Research Laboratories & Academic Institutes

10. Americas Cerebrovascular Diseases Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cerebrovascular Diseases Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cerebrovascular Diseases Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cerenovus Launched Cereglide 71 Intermediate Catheter for Revascularization in Patients with Acute Ischemic Stroke
    • 13.3.2. Enzene Biosciences Launched Biosimilar to Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (AMD)
    • 13.3.3. Cooper And Inspira Partner to Expand Neuroscience Care In South Jersey
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CEREBROVASCULAR DISEASES TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM CEREBROVASCULAR DISEAS